Hi, I'm Dan Pramak and welcome to Axios Recap, presented by Facebook.

Today is Monday, November 23rd.

Snapchat's TikTok clone is up, gold prices are down, and we're focused on how America could

be better prepared for another pandemic. Earlier today, AstraZeneca and the University of Oxford reported promising phase three clinical

trial data for their COVID-19 vaccine, following up on promising news earlier this month

from both Pfizer and Moderna.

All three vaccines could, at least in theory, be available to some people by the end of this year.

Now, conventional wisdom is that all three companies have moved at breathtaking speed

within the broader context of vaccine development and manufacturing, which often takes years.

And the same goes for a lot of the therapeutics developers, like Regeneron, which just got

FDA emergency use authorization for

the monoclonal antibody treatment that had been given to President Trump.

But there's also a different argument, one that says these processes only seem fast because

for decades there's been relatively little innovation in pharma manufacturing.

At least that's the feeling of Bob Nelson, one of the country's most

successful biotech venture capitalists. That's why Nelson spent the last several months

quietly working to launch a new company called Resilience, which formally launched today

with over $800 million in funding from companies like Google and a board of directors that

includes luminaries

like former FDA Commissioner Scott Gottlieb.

The basic idea is to revolutionize drug manufacturing within the United States to better

prepare us for whatever disease or public health crisis lies ahead.

...